Literature DB >> 16607627

Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease.

P González Carro1, F Pérez Roldán, O Roncero García Escribano, R Lafuente, M L Legaz Huidobro, A Amigo Echenagusía.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16607627     DOI: 10.1002/jca.20093

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


× No keyword cloud information.
  5 in total

1.  Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia.

Authors:  Tsutomu Mizoshita; Satoshi Tanida; Shigeru Kusumoto; Keiji Ozeki; Hironobu Tsukamoto; Masahide Ebi; Yoshinori Mori; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  Clin J Gastroenterol       Date:  2012-06-10

Review 2.  Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future.

Authors:  Xiu-Li Chen; Jing-Wei Mao; Ying-De Wang
Journal:  World J Gastrointest Pathophysiol       Date:  2020-05-12

Review 3.  Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy.

Authors:  Masahiro Iizuka; Takeshi Etou; Shiho Sagara
Journal:  World J Gastroenterol       Date:  2022-09-14       Impact factor: 5.374

4.  Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease.

Authors:  Keiji Ozeki; Satoshi Tanida; Tsutomu Mizoshita; Hironobu Tsukamoto; Masahide Ebi; Yoshinori Mori; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  Case Rep Gastroenterol       Date:  2012-12-20

Review 5.  Managing refractory Crohn's disease: challenges and solutions.

Authors:  Satoshi Tanida; Keiji Ozeki; Tsutomu Mizoshita; Hironobu Tsukamoto; Takahito Katano; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  Clin Exp Gastroenterol       Date:  2015-04-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.